In today’s recent session, 0.52 million shares of the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) have been traded, and its beta is 2.80. Most recently the company’s share price was $15.40, and it changed around -$0.1 or -0.65% from the last close, which brings the market valuation of the company to $796.18M. FDMT at last check was trading at a discount to its 52-week high of $36.25, offering almost -135.39% off that amount. The share price’s 52-week low was $9.44, which indicates that the recent value has risen by an impressive 38.7% since then. We note from 4D Molecular Therapeutics Inc’s average daily trading volume that its 10-day average is 0.75 million shares, with the 3-month average coming to 872.06K.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Instantly FDMT has been showing red trend so far today with a performance of -0.65% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 18.02 on recent trading dayincreased the stock’s daily price by 14.54%. The company’s shares are currently down -23.99% year-to-date, but still down -13.14% over the last five days. On the other hand, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is -32.13% down in the 30-day period. We can see from the shorts that 10.34 million shares have been sold at a short interest cover period of 14.24 day(s).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $40, which translates to bulls needing to increase their stock price by 61.5% from its current value. Analyst projections state that FDMT is forecast to be at a low of $30 and a high of $63.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
4D Molecular Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -53.63 percent over the past six months and at a -15.50% annual growth rate that is well below the industry average of 14.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 9.10% in revenue this quarter, and will report a decrease of -204.20% in the next quarter. The year-over-year growth rate is expected to be -73.20%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 1.31M in revenue for the current quarter. 8 analysts expect 4D Molecular Therapeutics Inc to make 640k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 850k and 20.2M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 54.10%. Forecasts for the next quarter put sales growth at -96.80%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.35%.
FDMT Dividends
4D Molecular Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Aug-07.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.50% of 4D Molecular Therapeutics Inc shares, and 110.44% of them are in the hands of institutional investors. The stock currently has a share float of 114.45%. 4D Molecular Therapeutics Inc stock is held by 208.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-03-31, it held 10.9495% of the shares, which is about 4.28 million shares worth $136.51 million.
RA CAPITAL MANAGEMENT, L.P., with 10.2523% or 5.05 million shares worth $160.94 million as of 2024-03-31, holds the second largest percentage of outstanding shares.
